The open-label study with nalmefene for as needed use in 45 alcohol-dependent patients deserves comment (Mueller et al., 2019). Regarding the safety issue in these patients with elevated liver stiffness and/or hepatic steatosis, in my opinion it is presumptuous in a series of only 45 patients with a 13% attrition rate to state that nalmefene “was generally well tolerated.”

中文翻译：

---

纳美芬根据需要使用需要危害/效益比的证据。

在 45 名酒精依赖患者中按需使用纳美芬的开放标签研究值得评论（Mueller等，2019）。关于这些肝脏硬度升高和/或肝脏脂肪变性患者的安全问题，在我看来，在一系列仅有 45 名流失率为 13% 的患者中声称纳美芬“总体耐受性良好”是不切实际的。